Research Triangle Park, NC (PRWEB) March 28, 2017
T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD), today announced that Dr. Kathleen Welsh-Bohmer has joined the Company’s Advisory Board.
CEO John Didsbury states, “As we seek to uniquely treat the metabolic dysfunctions inherent in Alzheimer’s disease and advance the clinical development of our drug candidate, T3D-959, beyond our recently completed exploratory Phase 2a trial, Dr. Welsh-Bohmer’s expertise in Alzheimer’s clinical trials will be invaluable.”
Dr. Kathleen Welsh-Bohmer is a Professor of Psychiatry and Neurology as well as the Chief of Medical Psychology, the professional home for the over 200 academic psychologists within Duke Medical Center. Clinically trained as a neuropsychologist, her research activities have been focused around developing effective prevention and treatment strategies to delay the onset of cognitive disorders occurring in later life. Since 2006 she has directed the Joseph and Kathleen Bryan Alzheimer’s Center in the Department of Neurology, where she leads a large multidisciplinary team focused on discovering the biological basis of Alzheimer’s disease and developing methods to enhance early diagnosis and speed drug discovery.
“The therapeutic focus on the fundamental upstream events contributing to Alzheimer’s neurogenesis is scientifically very appealing. T3D Therapeutics’ approach is novel and has the strong potential to have a positive impact on this catastrophic disease,” said Dr. Welsh-Bohmer.
About T3D Therapeutics, Inc.
T3D Therapeutics, Inc. is a privately-held, Research Triangle Park, NC-based company incorporated in 2013. The Company has an exclusive license to T3D-959, its lead product candidate, and a platform of structurally-related molecules. T3D Therapeutics’ mission is to develop and commercialize T3D-959 for the treatment of Alzheimer’s disease and Mild Cognitive Impairment. The Company believes, that due to its novel mechanism of action to improve aberrant glucose and lipid metabolism, T3D-959 may also have therapeutic benefit in other central nervous system and neurodegenerative diseases.
T3D-959, the Company’s lead product candidate, is a small molecule, orally-delivered, brain-penetrating PPAR delta / gamma dual nuclear receptor agonist. T3D-959 is designed to improve glucose and lipid metabolism dysfunctions present in Alzheimer’s disease. T3D-959 primarily activates PPAR delta and secondarily PPAR gamma. Unlike PPAR gamma, PPAR delta is universally expressed in the brain, particularly in areas of high energy metabolism. T3D-959 readily crosses the blood-brain barrier. In published preclinical studies T3D-959 has been observed to regulate Abeta, tau, oxidative stress and inflammation providing significant improvement in memory and motor function.
For more information, please visit http://www.t3dtherapeutics.com/.
Statements contained in this release that are not statements of historical fact are forward-looking statements, including those statements relating to the Company's expectations regarding clinical studies and developments, and the future potential of its product candidates, including T3D-959, and other statements that are predictive in nature or that depend upon or refer to future events or conditions. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important risks and uncertainties, and assumptions, which if they do not materialize or prove incorrect, may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company’s results include, but are not limited to, uncertainties and/or unexpected results related to research and development and clinical testing, the timing, costs and uncertainty of obtaining any required regulatory approvals, changes in the regulatory landscape, uncertainties related to obtaining additional capital as needed to meet the Company’s needs on acceptable terms, or at all, the absence of any guarantee of product demand, market acceptance or competitive advantage for any of the Company’s product candidates, if approved, and certain trade, legal, social and economic risks. Any forward-looking statement in this release speaks only as of the date on which it is made, and the Company assumes no obligation to update or revise any such forward-looking statement.
John Didsbury, Ph.D., CEO
T3D Therapeutics, Inc.
Email: info (at) t3dtherapeutics (dot) com